The DOI matches its Crossref record; 384 of the 384 references it cites were found in a registry or an index.
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
Open accessAbstract
A panel of experts was convened by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) to update the 2010 clinical practice guideline on Clostridium difficile infection (CDI) in adults. The update, which has incorporated recommendations for children (following the adult recommendations for epidemiology, diagnosis, and treatment), includes significant changes in the management of this infection and reflects the evolving controversy over best methods for diagnosis. Clostridium difficile remains the most important cause of healthcare-associated diarrhea and has become the most commonly identified cause of healthcare-associated infection in adults in the United States. Moreover, C. difficile has established itself as an important community pathogen. Although the prevalence of the epidemic and virulent ribotype 027 strain has declined markedly along with overall CDI rates in parts of Europe, it remains one of the most commonly identified strains in the United States where it causes a sizable minority of CDIs, especially healthcare-associated CDIs. This guideline updates recommendations regarding epidemiology, diagnosis, treatment, infection prevention, and environmental management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clostridium difficile is a Gram‐positive extracellular pathogen, which remains localized to the gastrointestinal tract but can cause severe toxin‐mediated gastrointestinal pathology, with a mortality rate of up to 6%. 67 , 68”
From The battle for iron in enteric infections (2020) · cites this paper as [68]
Citations
Cites
Multistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Stool form scale as a useful guide to intestinal transit time
Lewis, S. J., & Heaton, K. W. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011203 · Cited by 3,244
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Self-citationBurden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641
Self-citationDethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361
An Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Self-citationLoo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Self-citationGoing from evidence to recommendations
Guyatt, G. H., Oxman, A. D., Kunz, R., Falck-Ytter, Y., Vist, G. E., Liberati, A., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39493.646875.ae · Cited by 1,810
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
Research works printed but not linked: 3
- Health Protection Agency, 2005, Outbreak of Clostridium difficile infection in a hospital in southeast England, CDR Wkly, 15
- Tleyjeh, 2012, Association between acid-suppression therapy and Clostridium difficile infection: a systematic review and meta-analysis, Clin Microbiol Infect, 18, 113
- Polage, 2015, Overdiagnosis of Clostridium difficile infection in the molecular test era, JAMA Intern Med, 175, 1792, 10.1001/jamainternmed.2015.4114 · DOI · Paper page
Cited by
ACG Clinical Guideline: Ulcerative Colitis in Adults
Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G., & Long, M. D. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000152 · Cited by 1,577
“Although controlled trial data are limited, emerging evidence suggests a higher failure rate with metronidazole, suggesting that oral vancomycin should be the first-line agent for treatment of CDI in the hospitalized patient with ASUC (22,162).”
Practice Bulletin No. 183: postpartum hemorrhage
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002351 · Cited by 1,406
Gut microbial metabolites as multi-kingdom intermediates
Krautkramer, K. A., Fan, J., & Bäckhed, F. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0438-4 · Cited by 1,398
Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant
DeFilipp, Z., Bloom, P. P., Torres Soto, M., Mansour, M. K., Sater, M. R. A., Huntley, M. H., Turbett, S., Chung, R. T., Chen, Y.-B., & Hohmann, E. L. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910437 · Cited by 1,281
Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes
Guh, A. Y., Mu, Y., Winston, L. G., Johnston, H., Olson, D., Farley, M. M., Wilson, L. E., Holzbauer, S. M., Phipps, E. C., Dumyati, G. K., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910215 · Cited by 851
Self-citationHigh-Fat, Western-Style Diet, Systemic Inflammation, and Gut Microbiota: A Narrative Review
Malesza, I. J., Malesza, M., Walkowiak, J., Mussin, N., Walkowiak, D., Aringazina, R., Bartkowiak-Wieczorek, J., & Mądry, E. (2021) · Cells · doi:10.3390/cells10113164 · Cited by 782
“These include, for instance, fecal microbiota transplantation in recurrent Clostridium difficile infections or inflammatory bowel diseases [80,81].”
BackgroundClostridium difficile infection: review
Czepiel, J., Dróżdż, M., Pituch, H., Kuijper, E. J., Perucki, W., Mielimonka, A., Goldman, S., Wultańska, D., Garlicki, A., & Biesiada, G. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03539-6 · Cited by 702
Johnson, S., Lavergne, V., Skinner, A. M., Gonzales-Luna, A. J., Garey, K. W., Kelly, C. P., & Wilcox, M. H. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab549 · Cited by 674
“The previous iteration of the treatment guidelines recommended either vancomycin or fidaxomicin for treatment of an initial CDI episode for both nonsevere and severe (but not fulminant) disease [1].”
InfluentialSelf-citationvan Prehn, J., Reigadas, E., Vogelzang, E. H., Bouza, E., Hristea, A., Guery, B., Krutova, M., Norén, T., Allerberger, F., Coia, J. E., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.038 · Cited by 640
Self-citationMiller, J. M., Binnicker, M. J., Campbell, S., Carroll, K. C., Chapin, K. C., Gilligan, P. H., Gonzalez, M. D., Jerris, R. C., Kehl, S. C., Patel, R., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy381 · Cited by 641
Self-citationPoint-of-care diagnostics for infectious diseases: From methods to devices
Wang, C., Liu, M., Wang, Z., Li, S., Deng, Y., & He, N. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101092 · Cited by 622
Terreni, M., Taccani, M., & Pregnolato, M. (2021) · Molecules · doi:10.3390/molecules26092671 · Cited by 596
ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections
Kelly, C. R., Fischer, M., Allegretti, J. R., LaPlante, K., Stewart, D. B., Limketkai, B. N., & Stollman, N. H. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001278 · Cited by 579
“travenous metronidazole to oral vancomycin in patients with fulminant disease (1,3).”
BackgroundMethodInfluentialSelf-citationCammarota, G., Ianiro, G., Kelly, C. R., Mullish, B. H., Allegretti, J. R., Kassam, Z., Putignani, L., Fischer, M., Keller, J. J., Costello, S. P., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-319548 · Cited by 506
Self-citationKucharzik, T., Ellul, P., Greuter, T., Rahier, J. F., Verstockt, B., Abreu, C., Albuquerque, A., Allocca, M., Esteve, M., Farraye, F. A., et al. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab052 · Cited by 480
Miller, J. M., Binnicker, M. J., Campbell, S., Carroll, K. C., Chapin, K. C., Gilligan, P. H., Gonzalez, M. D., Jerris, R. C., Kehl, S. C., Patel, R., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy584 · Cited by 449
Self-citationMiller, J. M., Binnicker, M. J., Campbell, S., Carroll, K. C., Chapin, K. C., Gonzalez, M. D., Harrington, A., Jerris, R. C., Kehl, S. C., Leal, S. M., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae104 · Cited by 376
Self-citationMatson, V., Chervin, C. S., & Gajewski, T. F. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.11.041 · Cited by 385
Saint-Antoine IBD Network, Sokol, H., Landman, C., Seksik, P., Berard, L., Montil, M., Nion-Larmurier, I., Bourrier, A., Le Gall, G., Lalande, V., et al. (2020) · Microbiome · doi:10.1186/s40168-020-0792-5 · Cited by 378
Fecal microbiota transplantation: current challenges and future landscapes
Yadegar, A., Bar-Yoseph, H., Monaghan, T. M., Pakpour, S., Severino, A., Kuijper, E. J., Smits, W. K., Terveer, E. M., Neupane, S., Nabavi-Rad, A., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00060-22 · Cited by 351
Bacteria in cancer initiation, promotion and progression
El Tekle, G., & Garrett, W. S. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00594-2 · Cited by 343
Mullish, B. H., Quraishi, M. N., Segal, J. P., McCune, V. L., Baxter, M., Marsden, G. L., Moore, D. J., Colville, A., Bhala, N., Iqbal, T. H., et al. (2018) · Gut · doi:10.1136/gutjnl-2018-316818 · Cited by 332
The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications.
Allegretti, J. R., Mullish, B. H., Kelly, C., & Fischer, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31266-8 · Cited by 358
Self-citationGastrointestinal Tract Disorders in Older Age
Dumic, I., Nordin, T., Jecmenica, M., Stojkovic Lalosevic, M., Milosavljevic, T., & Milovanovic, T. (2019) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2019/6757524 · Cited by 314
Global burden of Clostridium difficile infections: a systematic review and meta-analysis
Balsells, E., Shi, T., Leese, C., Lyell, I., Burrows, J., Wiuff, C., Campbell, H., Kyaw, M. H., & Nair, H. (2019) · Journal of Global Health · doi:10.7189/jogh.09.010407 · Cited by 309
Baunwall, S. M. D., Lee, M. M., Eriksen, M. K., Mullish, B. H., Marchesi, J. R., Dahlerup, J. F., & Hvas, C. L. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100642 · Cited by 300
“difficile-associated diarrhoea (CDAD) as either i) clinical resolution of diarrhoea, or ii) persistent diarrhoea with a negative CD test [8,10].”
Khanna, S., Assi, M., Lee, C., Yoho, D., Louie, T., Knapple, W., Aguilar, H., Garcia-Diaz, J., Wang, G. P., Berry, S. M., et al. (2022) · Drugs · doi:10.1007/s40265-022-01797-x · Cited by 301
Probiotics in Medicine: A Long Debate
Stavropoulou, E., & Bezirtzoglou, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02192 · Cited by 282
Zhang, T., Lu, G., Zhao, Z., Liu, Y., Shen, Q., Li, P., Chen, Y., Yin, H., Wang, H., Marcella, C., et al. (2020) · Protein & Cell · doi:10.1007/s13238-019-00684-8 · Cited by 260
“© The Author(s) 2020 recommendation (McDonald et al., 2018; Ng et al., 2019).”
Marcella, C., Cui, B., Kelly, C. R., Ianiro, G., Cammarota, G., & Zhang, F. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16148 · Cited by 250
Self-citationPrevention of Infection After Gynecologic Procedures: ACOG Practice Bulletin, Number 195
(2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002670 · Cited by 244
Fecal Microbiota Transplantation: An Update on Clinical Practice
Kim, K. O., & Gluck, M. (2019) · Clinical Endoscopy · doi:10.5946/ce.2019.009 · Cited by 233
In Vivo Targeting of Clostridioides difficile Using Phage-Delivered CRISPR-Cas3 Antimicrobials
Selle, K., Fletcher, J. R., Tuson, H., Schmitt, D. S., McMillan, L., Vridhambal, G. S., Rivera, A. J., Montgomery, S. A., Fortier, L.-C., Barrangou, R., et al. (2020) · mBio · doi:10.1128/mbio.00019-20 · Cited by 228
Fecal Microbiota Transplantation for Primary Clostridium difficile Infection
Juul, F. E., Garborg, K., Bretthauer, M., Skudal, H., Øines, M. N., Wiig, H., Rose, Ø., Seip, B., Lamont, J. T., Midtvedt, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1803103 · Cited by 220
The promise of the gut microbiome as part of individualized treatment strategies
Schupack, D. A., Mars, R. A. T., Voelker, D. H., Abeykoon, J. P., & Kashyap, P. C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00499-1 · Cited by 217
Bassetti, M., Righi, E., Carnelutti, A., Graziano, E., & Russo, A. (2018) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2018.1522249 · Cited by 215
Introduction to host microbiome symbiosis in health and disease
Malard, F., Dore, J., Gaugler, B., & Mohty, M. (2021) · Mucosal Immunology · doi:10.1038/s41385-020-00365-4 · Cited by 209
Finn, E., Andersson, F. L., & Madin-Warburton, M. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06147-y · Cited by 207
ACG Clinical Guideline Update: Ulcerative Colitis in Adults
Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Barnes, E. L., & Long, M. D. (2025) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003463 · Cited by 194
Johnson, S., Lavergne, V., Skinner, A. M., Gonzales-Luna, A. J., Garey, K. W., Kelly, C. P., & Wilcox, M. H. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab718 · Cited by 208
Self-citationClostridioides difficile toxins: mechanisms of action and antitoxin therapeutics
Kordus, S. L., Thomas, A. K., & Lacy, D. B. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00660-2 · Cited by 204
Fletcher, J. R., Pike, C. M., Parsons, R. J., Rivera, A. J., Foley, M. H., McLaren, M. R., Montgomery, S. A., & Theriot, C. M. (2021) · Nature Communications · doi:10.1038/s41467-020-20746-4 · Cited by 196
The burden of CDI in the United States: a multifactorial challenge
Feuerstadt, P., Theriault, N., & Tillotson, G. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08096-0 · Cited by 181
Huttner, B. D., de Lastours, V., Wassenberg, M., Maharshak, N., Mauris, A., Galperine, T., Zanichelli, V., Kapel, N., Bellanger, A., Olearo, F., et al. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.12.009 · Cited by 174
The Use of Systemic and Topical Fluoroquinolones
Jackson, M. A., Schutze, G. E., COMMITTEE ON INFECTIOUS DISEASES, Byington, C. L., Maldonado, Y. A., Barnett, E. D., Campbell, J. D., Davies, H. D., Lynfield, R., Munoz, F. M., et al. (2016) · Pediatrics · doi:10.1542/peds.2016-2706 · Cited by 172
Gut microbiome in modulating immune checkpoint inhibitors
Li, X., Zhang, S., Guo, G., Han, J., & Yu, J. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104163 · Cited by 168
Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis
Bajaj, J. S., & Khoruts, A. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.01.017 · Cited by 167
Sartelli, M., Di Bella, S., McFarland, L. V., Khanna, S., Furuya-Kanamori, L., Abuzeid, N., Abu-Zidan, F. M., Ansaloni, L., Augustin, G., Bala, M., et al. (2019) · World Journal of Emergency Surgery · doi:10.1186/s13017-019-0228-3 · Cited by 159
Keller, J. J., Ooijevaar, R. E., Hvas, C. L., Terveer, E. M., Lieberknecht, S. C., Högenauer, C., Arkkila, P., Sokol, H., Gridnyev, O., Mégraud, F., et al. (2021) · United European Gastroenterology Journal · doi:10.1177/2050640620967898 · Cited by 160
Bella, S. D., Sanson, G., Monticelli, J., Zerbato, V., Principe, L., Giuffrè, M., Pipitone, G., & Luzzati, R. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00135-23 · Cited by 227
de Jonge, S. W., Boldingh, Q. J. J., Solomkin, J. S., Dellinger, E. P., Egger, M., Salanti, G., Allegranzi, B., & Boermeester, M. A. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30084-0 · Cited by 158
McGovern, B. H., Ford, C. B., Henn, M. R., Pardi, D. S., Khanna, S., Hohmann, E. L., O’Brien, E. J., Desjardins, C. A., Bernardo, P., Wortman, J. R., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa387 · Cited by 159
“Finally, the incorporation of toxin testing will allow accurate assessment of efficacy and safety of this investigational microbiome agent [30, 37].”
BackgroundMethodInfections in the Elderly Critically-Ill Patients
Eşme, M., Topeli, A., Doğu, B. B., & Akova, M. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00118 · Cited by 187
Assessing Severity of Disease in Patients with Ulcerative Colitis
Pabla, B., & Schwartz, D. A. (2020) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2020.08.003 · Cited by 174
Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology
Khoruts, A., Staley, C., & Sadowsky, M. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0350-4 · Cited by 155
Sholeh, M., Krůtová, M., Forouzesh, M., Mironov, S. P., Sadeghifard, N., Molaeipour, L., Maleki, A., & Kouhsari, E. (2020) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-020-00815-5 · Cited by 155
Petty, L. A., Vaughn, V. M., Flanders, S. A., Malani, A. N., Conlon, A., Kaye, K. S., Thyagarajan, R. V., Osterholzer, D., Nielsen, D. L., Eschenauer, G. A., et al. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.2871 · Cited by 169
Reorganisation of Faecal Microbiota Transplant Services During the COVID-19 Pandemic
Ianiro, G., Mullish, B. H., Kelly, C. R., Kassam, Z., Kuijper, E. J., Ng, S. C., Iqbal, T. H., Allegretti, J. R., Bibbò, S., Sokol, H., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-321829 · Cited by 147
Self-citationFecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes?
Aron‐Wisnewsky, J., Clément, K., & Nieuwdorp, M. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1180-z · Cited by 160
Cheng, Y., Phelps, E. L., Ganapini, V., Khan, N. U. A., Ouyang, F., Xu, H., Khanna, S., Tariq, R., Friedman‐Moraco, R., Woodworth, M. H., et al. (2018) · American Journal of Transplantation · doi:10.1111/ajt.15058 · Cited by 141
Dubberke, E. R., Lee, C. H., Orenstein, R., Khanna, S., Hecht, G., & Gerding, D. N. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy259 · Cited by 140
Self-citationAntibiotic-induced collateral damage to the microbiota and associated infections
de Nies, L., Kobras, C. M., & Stracy, M. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00936-9 · Cited by 169
Clostridioides difficile Infection
Guh, A. Y., & Kutty, P. K. (2018) · Annals of Internal Medicine · doi:10.7326/aitc201810020 · Cited by 159
Dsouza, M., Menon, R., Crossette, E. M., Bhattarai, S. K., Schneider, J., Kim, Y., Reddy, S., Caballero, S., Felix, C. R., Cornacchione, L. P., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.03.016 · Cited by 150
Self-citationPlasmid-mediated metronidazole resistance in Clostridioides difficile
Boekhoud, I. M., Hornung, B., Sevilla, E., Harmanus, C., Sanders, I. M. J. G., Terveer, E. M., Bolea, R., Corver, J., Kuijper, E. J., & Smits, W. K. (2020) · Nature Communications · doi:10.1038/s41467-020-14382-1 · Cited by 143
Tang, B., Tang, L., Li, S., Liu, S., He, J., Li, P., Wang, S., Yang, M. J., Zhang, L., Lei, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36981-4 · Cited by 152
Baunwall, S. M. D., Paaske, S. E., Hansen, M. M., Kelsen, J., Høyer, K. L., Rågård, N., Eriksen, L. L., Støy, S. H., Rubak, T., Damsgaard, E. M. S., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00276-x · Cited by 145
Lopetuso, L. R., Deleu, S., Godny, L., Petito, V., Puca, P., Facciotti, F., Sokol, H., Ianiro, G., Masucci, L., Abreu, M., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-329948 · Cited by 129
Davidovics, Z. H., Michail, S. K., Nicholson, M. R., Kociolek, L. K., Pai, N., Hansen, R., Schwerd, T., Maspons, A., Shamir, R., Szajewska, H., et al. (2018) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002205 · Cited by 140
“Alternatively, the toxin assay sensitivity may be optimized with a 2-step testing strategy: glutamate dehydrogenase (highly sensitive for C difficile but does not distinguish toxigenic from nontoxigenic C difficile strains), and if positive, follow-up testing with NAAT as a confirmatory method (4).”
BackgroundMethodInfluentialLiu, J.-Y., & Dickter, J. K. (2020) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2020.06.001 · Cited by 166
Crothers, J. W., Chu, N. D., Nguyen, L. T. T., Phillips, M., Collins, C. C., Fortner, K. A., del Río, R., Lavoie, B. A., CALLAS, P. W., Velez, M., et al. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01856-9 · Cited by 140
Acute Infectious Diarrhea and Gastroenteritis in Children
Flórez, I. D., Niño-Serna, L. F., & Beltrán-Arroyave, C. (2020) · Current Infectious Disease Reports · doi:10.1007/s11908-020-0713-6 · Cited by 152
“Clostridium difficile toxins produce antibiotic-associated diarrhea (AAD) and is a leading cause of disease in hospitalized children and adults [11].”
BackgroundJayatilleke, K. (2020) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-020-00229-2 · Cited by 132
Update on the adverse effects of antimicrobial therapies in community practice.
Mohsen, S. T., Dickinson, J. A., & Somayaji, R. (2020) · PubMed · Cited by 217
Fecal Microbiota Transplantation: Screening and Selection to Choose the Optimal Donor
Bibbò, S., Settanni, C. R., Porcari, S., Bocchino, E., Ianiro, G., Cammarota, G., & Gasbarrini, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061757 · Cited by 137
Gut microbiome health and dysbiosis: A clinical primer
Bidell, M. R., Hobbs, A. L. V., & Lodise, T. P. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2731 · Cited by 160
Gut microbiota and old age: Modulating factors and interventions for healthy longevity
Coman, V., & Vodnar, D. C. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.111095 · Cited by 140
“difficile infection who have failed appropriate antibiotic treatments (strong recommendation, moderate quality of evidence)” (McDonald et al., 2018).”
Ke, S., Pollock, N. R., Wang, X., Chen, X., Daugherty, K., Lin, Q., Xu, H. J., Garey, K. W., Gonzales-Luna, A. J., Kelly, C. P., et al. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1935186 · Cited by 123
Self-citationFordyce, C. B., Katz, J. N., Alviar, C. L., Arslanian-Engoren, C., Bohula, E. A., Geller, B. J., Hollenberg, S. M., Jentzer, J. C., Sims, D. B., Washam, J. B., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000909 · Cited by 116
Revolinski, S., & Munoz-Price, L. S. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy845 · Cited by 111
Koh, E., Hwang, I. Y., Lee, H. L., Sotto, R. D., Lee, J. W. J., Lee, Y. S., March, J. C., & Chang, M. W. (2022) · Nature Communications · doi:10.1038/s41467-022-31334-z · Cited by 116
Delivery routes for faecal microbiota transplants: Available, anticipated and aspired
Gulati, M., Singh, S. K., Corrie, L., Kaur, I. P., & Chandwani, L. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104954 · Cited by 121
Staley, C. M., Kaiser, T., Vaughn, B. P., Graiziger, C. T., Hamilton, M. J., Rehman, T. U., Song, K., Khoruts, A., & Sadowsky, M. J. (2018) · Microbiome · doi:10.1186/s40168-018-0549-6 · Cited by 108
“societies and incorporated into standard treatment guidelines as an option following failure of antibiotic treatment [4, 5].”
BackgroundIaniro, G., Murri, R., Sciumè, G. D., Impagnatiello, M., Masucci, L., Ford, A. C., Law, G. R., Tilg, H., Sanguinetti, M., Cauda, R., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m18-3635 · Cited by 109
The Intestinal Microbiota: Impacts of Antibiotics Therapy, Colonization Resistance, and Diseases
Shah, T., Baloch, Z., Shah, Z., Cui, X., & Xia, X. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126597 · Cited by 106
Strategies to prevent Clostridioides difficile infections in acute-care hospitals: 2022 Update
Kociolek, L. K., Gerding, D. N., Carrico, R., Carling, P., Donskey, C. J., Dumyati, G. K., Kuhar, D. T., Loo, V. G., Maragakis, L. L., Pogorzelska‐Maziarz, M., et al. (2023) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2023.18 · Cited by 120
Self-citationClostridioides difficile: diagnosis and treatments
Guery, B. P., Galpérine, T., & Barbut, F. (2019) · BMJ · doi:10.1136/bmj.l4609 · Cited by 162
Assadian, O., Harbarth, S., Vos, M. D., Knobloch, J. K. ‐., Asensio, Á., & Widmer, A. F. (2021) · Journal of Hospital Infection · doi:10.1016/j.jhin.2021.03.010 · Cited by 154
Haifer, C., Kelly, C. R., Paramsothy, S., Andresen, D. N., Papanicolas, L. E., McKew, G. L., Borody, T. J., Kamm, M. A., Costello, S. P., Andrews, J. M., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-320260 · Cited by 113
Self-citationSepsis and the Microbiome: A Vicious Cycle
Miller, W. D., Keskey, R. C., & Alverdy, J. C. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa682 · Cited by 117
“First and foremost in this approach may be to follow various society guidelines on antibiotic stewardship [35].”
BackgroundPollock, N. R., Banz, A., Chen, X., Williams, D. N., Xu, H. J., Cuddemi, C., Cui, A. X., Perrotta, M., Alhassan, E., Riou, B., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy415 · Cited by 102
Self-citationBaktash, A., Terveer, E. M., Zwittink, R. D., Hornung, B., Corver, J., Kuijper, E. J., & Smits, W. K. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01242 · Cited by 142
Saha, S., Mara, K. C., Pardi, D. S., & Khanna, S. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.01.010 · Cited by 107
Balram, B., Battat, R. J., Khoury, A. A., D’Aoust, J., Afif, W., Bitton, A., Lakatos, P. L., & Bessissow, T. (2018) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjy143 · Cited by 101
Mamic, P., Chaikijurajai, T., & Tang, W. H. W. (2020) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.12.001 · Cited by 105
Dampak Pembelajaran Daring terhadap Perilaku Sosial Emosional Anak
Kusuma, W. S., & Sutapa, P. (2020) · Jurnal Obsesi Jurnal Pendidikan Anak Usia Dini · doi:10.31004/obsesi.v5i2.940 · Cited by 100
The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey
Baunwall, S. M. D., Terveer, E. M., Dahlerup, J. F., Erikstrup, C., Arkkila, P. E. T., Vehreschild, M. J. G. T., Ianiro, G., Gasbarrini, A., Sokol, H., Kump, P. K., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100181 · Cited by 108
Shiga Toxin–Producing Escherichia coli Transmission via Fecal Microbiota Transplant
Zellmer, C., Sater, M. R. A., Huntley, M. H., Osman, M., Olesen, S. W., & Ramakrishna, B. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1486 · Cited by 98
Piano, S. S., Bunchorntavakul, C., Marciano, S., & Reddy, K. R. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00078-5 · Cited by 107
Epidemiology of community-acquired and recurrent Clostridioides difficile infection
Fu, Y., Luo, Y., & Grinspan, A. M. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211016248 · Cited by 106
Metadata
- Authors
- McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., Loo, V., Shaklee Sammons, J., Sandora, T. J., & Wilcox, M. H.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Edward Hines, Jr. VA Hospital (US)
- Loyola University Medical Center (US)
- St. Luke's Hospital (US)
- Johns Hopkins University (US)
- Children's Hospital of Philadelphia (US)
- Washington University in St. Louis (US)
- University of Houston (US)
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
- McGill University Health Centre (CA)
- Children’s Hospital of Philadelphia, Pennsylvania
- Boston Children's Hospital (US)
- Leeds Teaching Hospitals NHS Trust (GB)
- Corresponding author
- McDonald, L Clifford
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-02-15
- Volume
- 66
- Issue
- 7
- Pages
- e1-e48
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC6018983
- OpenAlex
- W2791326569
- Cited by
- 2,690
- References
- 383
- Citations by year
- 2026: 148 · 2025: 179 · 2024: 215 · 2023: 305 · 2022: 331 · 2021: 423 · 2020: 486 · 2019: 408 · 2018: 185
- FWCI
- 228.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- Funders
- Agency for Health Research and Quality
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Keywords
- Clostridium difficile infection, nosocomial infections, healthcare-associated diarrhea, pediatric infection, diagnosis, treatment, infection control, environmental management, ribotype 027, community-acquired infections, epidemiology
- MeSH terms
- Adult, Child, Clostridium Infections, Diarrhea, Humans, Retrospective Studies, Societies, Societies, Medical, Clostridioides difficile, Infectious Disease Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.